A new study found that the topical application of simvastatin enhanced
healing in diabetic mice.
Using a statin, a cholesterol-lowering drug, as an ointment may hold
promise for helping people with diabetes, a study suggests. The new study found
that the topical application of simvastatin accelerated wound healing in
genetically diabetic mice. The findings were published in the December issue of
The American Journal of Pathology. Though the work was done in mice, the
researchers hope the benefits will apply to humans as well once tried in future
studies. Previous research has shown that statins can support blood vessel
development, according to the study.
If statins are applied topically instead of taken orally, there are
fewer risks of serious side effects. Topical applications of medications have
less side effects systemically, said Rita Kalyani, an assistant professor of
medicine in the Division of Endocrinology and Metabolism at Johns Hopkins
University in Baltimore. She was not involved in the study. Scientists at Kyoto
Prefectural University School of Medicine, Hamamatsu University School of
Medicine and the Shiseido Innovative Scientific Research Center in Japan tested
whether a statin's ability to promote blood vessel growth could help in
diabetes. In diabetes, the body does not sufficiently make or properly use
insulin, a hormone. With such a problem, sugar builds in the blood. This
condition can harm blood vessels and nerves. Diabetes complications include
skin ulcers and impaired wound healing.
The researchers treated wounds on the mice with a topical application of
simvastatin in petroleum jelly or petroleum jelly alone. The difference in
wound closure was most pronounced on the seventh day of the experiment. The
simvastatin-treated wounds were 79.26% healed. The wounds treated with just
petroleum jelly were 52.45% healed.
The findings show that topical simvastatin increases the growth of new
blood and lymphatic vessels, Jun Asai, the study's lead author, said in a
statement. Lymphatic vessels, which carry lymph fluid through the body, support
the immune system. "Although there are several problems to be solved such
as the establishment of proper concentrations and the frequency of application,
it is my emphatic opinion that this method … can be a new effective choice for
the treatment of diabetic ulcers," Asai, of Kyoto Prefectural University
School of Medicine, said in an e-mail.
David Armstrong, a professor of surgery at the University of Arizona
College of Medicine, urged caution. "It is very premature to draw a broad
conclusion based on this study. It is a mouse study." Armstrong, who was
not involved in this experiment, said seeing whether this study can be
replicated and taken to the level of human trials could further test this
approach. Johns Hopkins' Kalyani called the study "relatively small"
and said more research needs to be done on the topical formulation of
simvastatin, its potential side effects and the durability of its effect. The
Centers for Disease Control and Prevention and the International Diabetes
Federation project the number of diabetes cases will continue to increase,
Kalyani said. "There is definitely a need for this kind of research to be
done."
USA Today
No comments:
Post a Comment